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Activation of mammalian innate and acquired immune responses
must be tightly regulated by elaborate mechanisms to control their
onset and termination. MicroRNAs have been implicated as neg-
ative regulators controlling diverse biological processes at the level
of posttranscriptional repression. Expression profiling of 200 mi-
croRNAs in human monocytes revealed that several of them
(miR-146ab, miR-132, and miR-155) are endotoxin-responsive
genes. Analysis of miR-146a and miR-146b gene expression un-
veiled a pattern of induction in response to a variety of microbial
components and proinflammatory cytokines. By means of pro-
moter analysis, miR-146a was found to be a NF-B-dependent
gene. Importantly, miR-146ab were predicted to base-pair with
sequences in the 3 UTRs of the TNF receptor-associated factor 6
and IL-1 receptor-associated kinase 1 genes, and we found that
these UTRs inhibit expression of a linked reporter gene. These
genes encode two key adapter molecules downstream of Toll-like
and cytokine receptors. Thus, we propose a role for miR-146 in
control of Toll-like receptor and cytokine signaling through a
negative feedback regulation loop involving down-regulation of
IL-1 receptor-associated kinase 1 and TNF receptor-associated fac-
tor 6 protein levels.
immunity  microRNA  LPS  Toll-like receptor
Innate immunity is the first line of host defense, designed torecognize pathogen-associated molecular patterns repre-
sented by conserved components of microorganisms unique to
the microbial world. The pathogen molecules are detected via a
limited number of germ line-encoded receptors expressed in
immune cells, such as macrophages and dendritic cells. In the last
decade, members of the Toll-like receptor (TLR) family have
emerged as the primary evolutionarily conserved sensors of
pathogen-associated molecular patterns (1). Binding of the
TLRs to their respective ligands initiates a wide spectrum of
responses from phagocytosis to production of a variety of
cytokines, which in turn shape and enhance the inflammatory
and adaptive immune responses.
All TLR receptors trigger signals in a similar fashion because of
the presence of Toll and IL-1 receptor (TIR) domains in their
cytoplasmic tails. The signaling cascade of TLR4, the founding
member of the family and a sensor of LPS, is initiated when adaptor
proteins MyD88 and TIR domain-containing adaptor-inducing
IFN- (TRIF) are recruited to the receptor, activating two inde-
pendent branches of TLR signaling. MyD88 serves as a bridge
between TLR4 and IL-1 receptor associated kinase (IRAK1) that
then recruits into the complex TNF receptor-associated factor 6
(TRAF6). This chain of events triggers activation of IB kinase and
JNK and, in turn, the downstream NF-B and AP-1 transcription
factors and results in up-regulation of immune-responsive genes (2).
The TRIF-dependent branch of signaling leads to the activation of
another group of transcription factors, the IRF family, and results
in a boost of expression of IFNs and other genes.
TLRs are double-edged swords because abnormal activation of
their signaling can be deleterious. Thus, it is not surprising that a
distinct group of TLR-activated genes is involved in modulation of
TLR signal transduction by interfering with upstream signaling
pathways. Several classes of negative regulators of the TLR system
have been described in the past: soluble decoy receptors (sTLR2
4), cell-surface transmembrane receptors (ST2, SIGRR, and
TRAILR), and numerous intracellular proteins: IRAK-M, sup-
pressor of cytokine signaling 1 (SOCS1), MyD88 short (MyD88s),
inhibitor of NF-B (IB), and A20 (3).
MicroRNAs (miRNAs) are an evolutionarily conserved class of
endogenous 22-nt noncoding RNAs involved in posttranscrip-
tional gene repression (4–6). In animals, miRNAs are processed
from long primary transcripts [pri-miRNAs (pri-miR)] through an
60-bp hairpin precursor step [pre-miRNAs (pre-miR)] into the
mature forms by sequential cutting with two RNase III enzymes,
Drosha and Dicer (7, 8). Mature miRNAs are then loaded onto the
ribonucleoprotein complex dubbed RISC (RNA-induced silencing
complex), where they guide the recognition and translational
repression or degradation of target mRNAs. pri-miRNAs are
transcribed by RNA polymerase II and thus are subject to regula-
tion by the assortment of transcription factors in the cell (9–11).
Whereas some miRNAs are widely expressed, others exhibit only
limited developmental stage-, tissue-, or cell type-specific patterns
(12). In mammals, miRNAs have been associated with diverse
biological processes, such as cell differentiation (13–15), cancer
(16–18), regulation of insulin secretion (19), and viral infection (20,
21). Studies in plants have shown that miRNAs can be involved in
responses to a variety of environmental stresses (22–25). However,
understanding of the regulation and function of the bulk of miRNA
genes await further investigation.
To examine the potential involvement of miRNAs in regula-
tion of the innate immune response, we analyzed expression of
200 miRNAs after exposure of THP-1 cells to LPS. We show that
production of mature forms for several of them (miR-146ab,
miR-132, and miR-155) is induced, and we provide here a
detailed profile of expression of one miRNA family from this
group (miR-146ab) in response to various microbial compo-
nents and proinflammatory mediators. Promoter analysis of the
miR-146a gene revealed that NF-B plays a critical role in
induction of its transcription by LPS, TNF, and IL-1. In
addition, we have determined that TRAF6 and IRAK1 repre-
sent potential molecular targets of miR-146 through experiments
with 3 UTR luciferase reporters. These findings suggest that
miR-146ab may function as novel negative regulators that help
to fine-tune the immune response.
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Results
To identify miRNA genes whose expression might be regulated by
innate immunity receptors, we analyzed the expression profile of
the human acute monocytic leukemia cell line THP-1 using a DNA
microarray containing 200 oligonucleotide probes complementary
to mature forms of miRNAs of human, mouse, and rat origin. After
an LPS challenge, the array revealed up-regulation in the expression
of the miR-146, miR-155, and miR-132 genes (Fig. 1A). This result
was validated by quantitative RT-PCR (qPCR) analysis of levels of
miR-146, miR-155, and miR-132 in LPS-stimulated THP-1 cells
using primers that recognize their respective mature forms (data
not shown).miR-146was chosen for detailed analysis in the present
study.
The rapid induction of miR-146 in response to LPS, as shown by
qPCR, suggested that miR-146 might be an LPS primary-response
gene (Fig. 1B). Its expression reached a plateau 8 h after LPS
challenge.
The human genome contains two miR-146 genes [miR-146a (26)
and miR-146b (27)] on chromosomes 5 and 10, respectively, and
their mature products differ only by 2 nt in the 3 region (Fig. 4,
which is published as supporting information on the PNAS web
site). To study them individually using qPCR proved difficult
because primers were unable to distinguish between the mature
species (data not shown). Thus, we resorted to Northern blot
analysis using DNA oligonucleotide probes complementary to the
mature sequences. Hybridization of total RNA from 293IL1R
MD2TLR4 cells expressing either pre-miR-146a or pre-miR-146b
under the control of the CMV promoter confirmed the ability of the
probes to discriminate between the two miR-146 isoforms (Fig. 1C,
lanes 5–7). Northern blot analysis of miR-146a expression in two
human cell lines of myeloid origin (THP-1 and HL-60) has shown
that it is strongly induced after 8 h of LPS treatment (Fig. 1C Top,
lanes 1–4). By this method, miR-146b could not be detected before
or after induction (Middle). As a control, miR-16 was not affected
by LPS (Bottom). Levels of LPS-induced miR-146a comparable to
Fig. 1. miRNAmiR-146a is an immediate early-responsegene inducedby variousmicrobial components andproinflammatorymediators. (A)Microarray analysis
ofmiRNAexpression in THP-1 cells after stimulationwith LPS (E. coli strain 055:B5). The scatter plot showsaveraged (n4) background-subtracted raw intensities
for eachprobeonboth channels for Cy3-labeled control andCy5-labeled 8-h LPS-treated samples. Each dot represents onemiRNAprobe. (B) Kinetics ofmiR-146a
up-regulation by LPS. THP-1 cells were stimulated with LPS for the indicated times, and miR-146 expression was analyzed by qPCR and normalized by using 5S
RNA levels. (C) Northern blot analysis of miR-146ab expression. Indicated human cell lines were treated with LPS (E. coli strain 055:B5) for 8 h and probed with
DNAoligonucleotides complementary tomaturemiR-146a (Top) andmiR-146b (Middle). To assess the specificity of the probes, we used total RNA from 293 cells
transiently transfectedwith pcDNA3 vector or expressionplasmids for either pre-miR-146aor pre-miR-146b (marked as C, A, andB, respectively). (The faint bands
in the lanesprobed formiR-146bare cross-reactionswithmirR-146abands; thedarkband in lane6 representsmiR-146b.) Themembranewas reprobed formiR-16
as a loading control (Bottom). Radiolabeled RNA decade marker was used as a molecular weight reference. (D) Analysis of miR-146 expression in response to
a panel of innate immunity ligands. THP-1 cells were stimulated with the indicated stimuli for 8 h. miR-146 expression was analyzed by qPCR and normalized
by using 5S RNA levels.
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that in THP-1 were observed in several other cell lines of myeloid
origin, e.g., human U937, Mono-Mac-6, and mouse WEHI-3 (data
not shown). At the same time, human B cell lines Ramos, Bjab, and
Namalwa showed no increase in mature miR-146a levels in re-
sponse to LPS (data not shown).
LPS signals through TLR4 (28), a member of the Toll family of
pattern-recognition receptors, which consists of 10 members in
humans (29). We investigated whether miR-146ab expression
might be regulated by other TLRs as well as the proinflammatory
cytokines IL-1 and TNF. Ultrapure LPS (from Escherichia coli
strain K12 and Salmonella minnesota) consistently produced lower
levels of miR-146 up-regulation than did crude preparations of LPS
(Fig. 1D), suggesting that other components of the bacterial cell wall
in crude preparations of LPS might contribute to miR-146 induc-
tion. Indeed, we found that miR-146 expression was significantly
induced after exposure of THP-1 cells to peptidoglycan and its
synthetic analog, Pam3CSK4, both of which trigger TLR2 signaling
(Fig. 1D). Peptidoglycan is characteristic of both Gram-negative
and Gram-positive bacteria but is highly enriched in the bacterial
cell wall of the latter. Treatment of THP-1 cells with flagellin, a
major component of the bacterial flagellar filament and agonist of
the TLR5 receptor, also resulted in increased miR-146 expression
(Fig. 1D). In contrast, stimulation of TLR3, TLR7, and TLR9 by
their respective agonistic ligands did not affect miR-146 expression
(Fig. 1D). Proinflammatory cytokines TNF and IL-1 produced
modest increases in miR-146 levels in THP-1 cells, whereas treat-
ment with CD40L or with the phorbol myristyl acetateionomycin
combination showed no effect.
Human miR-146a resides in the LOC285628 gene on human
chromosome 5. Analysis of the two ESTs encompassing
LOC285628 (GenBank accession nos. BQ430527 and BQ425371)
suggests that the gene consists of two exons separated by16 kb of
genomic sequence, with the mature miR-146a sequence situated in
the second exon (Fig. 2A). Notably, the LOC285628 transcript
Fig. 2. miR-146a is an NF-B-dependent gene. (A) Schematic diagrams ofmiR-146a (Upper) andmiR-146b (Lower) genomic loci on human chromosomes 5 and
10, respectively. Putative binding sites of NF-B (black), IRF37 (gray), and CEBP (white, partially overlaps with IRF37) transcriptional factors are shown as
boxes. Genomic regions indicated by bars above themiR-146a locus were analyzed in promoter luciferase reporter assay (C). Mutations, disrupting transcription
factor binding introduced in the A547 construct, are indicated by X, and the sequences of mutated sites are shown under the locus diagram. (B) Northern blot
analysis of pri-miR-146a and pri-miR-146b expression in the THP-1 cell line. Cells were starved for 24 h and then stimulated with LPS for 8 h. Northern blots were
hybridized with radiolabeled pre-miR-146a or pre-miR-146b probes, respectively. -Actin (Northern blot) and 18S rRNA (methylene blue staining) levels are
shown as loading controls. (C) miR-146a promoter analysis. Promoter constructs containing genomic fragments of miR-146a locus were transfected into the
293IL-1RTLR4MD2 cell line. Cells were stimulatedwith TNF (white bars), IL-1 (gray bars), or LPS (black bars) for 8 h and analyzed by luciferase reporter assay.
Promoter regions used in this experiment are depicted schematically in A.
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contains no significant ORF, implying that it probably belongs to a
class of noncoding RNAs. Using the 3- and 5-RACE technique we
confirmed the two-exon structure of the miR-146a primary tran-
script (pri-miR146a). However, we noticed that its previous char-
acterization was incomplete, and its full length is, in fact, 2,337 bp.
Human miR-146b is located on chromosome 10, yet its sequence
is not included in any of the previously cloned ESTs. Our 5-RACE
results indicate that its transcript consists of only one exon with the
transcription start site located 700 bp upstream of the mature
miR-146b sequence (Fig. 2A).
To determine the effect of LPS on pri-miR-146a expression, we
analyzed total RNA from LPS-stimulated and control THP-1 cells
by Northern blot with a probe corresponding to pre-miR146a. We
found that whereas the basal level of pri-miR-146a expression is
undetectable in untreated cells, exposure of THP-1 cells to LPS for
8 h resulted in the appearance of four distinct bands. Two of these
bands were of high molecular weight (9 kb), probably correspond-
ing to unspliced miR-146a transcripts, whereas one of the lower
bands with the calculated size of 2.3 kb exactly matched the size of
pri-miR-146a determined by our RACE experiments (Fig. 2B).
Analysis of the same RNAs from THP-1 cells with a pre-miR-146b
probe revealed that the primary transcript of this miRNA is also
inducible by LPS despite our inability to visualize its mature form.
To understand the pathway by which pri-miR-146a was induced
by LPS, we first characterized the miR-146a promoter region using
the Genomatix MatInspector software package, focusing on those
transcription factors that are common to TLR4, IL-1, and TNF
signaling. A scan of 1.5 kb of genomic sequence located upstream
of the predicted pri-miR-146a start site identified three putative
NF-B (30) and two IRF3IRF7 consensus binding sites (31) (Fig.
2A). One of the identified IRF37 sites overlaps with the site for
CEBP (NF-IL6) (32). We examined the role of the predicted
transcriptional binding sites in induction of miR-146a expression by
generating a series of miR-146a promoter constructs (Fig. 2A) and
testing them in a luciferase reporter assay. As shown in Fig. 2C, a
miR-146a promoter is found in the upstream 550 bp, and its LPS
responsiveness is totally dependent on the NF-B binding sites.
Activation of the miR-146a promoter construct by TNF and IL-1
was also impaired by mutations in these sites (Fig. 2C). In contrast,
we found no role for the IRF37 site because mutations of the site
had no effect on induction of the luciferase reporter (Fig. 2C).
To study the functional consequences of miR-146 induction by
LPS we searched for predicted mRNA target sites. 3 UTRs of
mRNAs encoding IRAK1, TRAF6, and COTTpl2MAP3K8
proteins were found to contain miR-146 target sequences by several
prediction algorithms (33–36). Whereas COTTpl2MAP3K8
mRNA had only one miR-146 target sequence, TRAF6 and
IRAK1 mRNAs contained multiple sites (Fig. 5, which is published
as supporting information on the PNAS web site). IRAK1 and
TRAF6 are key adapter molecules in TLR and IL-1 receptor
signaling cascades, mediating activation of NF-B and AP-1 path-
ways. COTTpl2 is a serinethreonine protein kinase that is
essential for ERK activation downstream of TLRs IL-1 and TNF
receptors (37).
To test the possibility that expression of these three miR-146ab
target genes is regulated posttranscriptionally by miR-146, we
generated reporter constructs that contain the firefly luciferase
gene fused to500 bp of the 3UTRs from IRAK1, TRAF6, and
COT1 mRNAs containing putative miR-146 target sites (IRAK1-
UTR, TRAF6-UTR, and COT1-UTR, respectively) (Fig. 5). These
reporter constructs were transiently transfected into 293 cells
together with an expression plasmid for either miR-146a or miR-
146b under the control of the CMV promoter. We observed a
marked reduction in luciferase levels in cells coexpressing miR-146a
together with IRAK1-UTR and TRAF6-UTR (Fig. 3A). In con-
trast, no changes in COT1-UTR reporter plasmid expression were
observed in the presence of miR-146a. We also found that miR-
146b is capable of repressing the IRAK1-UTR and TRAF6-UTR
reporter constructs despite having a 2-nt difference from miR-146a
at its 3 end. Specificity of the miR-146ab effect on IRAK1-UTR
and TRAF6-UTR reporters was suggested by the lack of change of
their levels of expression in the presence of an irrelevant miRNA,
miR-21. Moreover, mutation of 4 nt in the miR-146ab target
sequences led to a complete abrogation of the negative effect of
these miRNAs on expression of IRAK1-UTR and TRAF6-UTR
reporter constructs (Fig. 3). These data suggest that the IRAK1 and
TRAF6 genes are targets for posttranscriptional repression by
miR-146ab in vivo.
Discussion
An appropriate innate immune response is required to defend an
organism against various pathogens, but if induced either too
Fig. 3. IRAK1 and TRAF6may bemolecular targets of
miR-146 posttranscriptional repression. Shown is a se-
quence alignment ofmiR-146a and its target sites in 3
UTRs of TRAF6 (A) and IRAK1 (B). Also shown is an
analysis of expression of TRAF6-UTR (A) and IRAK1-
UTR (B) luciferase reporters in the presence of miR-
146ab or the irrelevant control miR-21. Filled bars
correspond to reporter constructs with wild-type miR-
146 targeting sites, and open bars correspond to con-
structs with 4-nt substitutions disrupting base-pairing
with the ‘‘seed region’’ of miR-146. In IRAK1-UTR-mut
both miR-146-binding sites were mutated as shown.
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strongly or for too long the response can be harmful, causing the
pathological manifestations of both acute and chronic inflamma-
tory disorders. Thus, cells of the immune system must employ a
multilayered control system to keep innate immunity and inflam-
mation in check. Although some of these negative regulation
mechanisms have been uncovered in the past (3), we are probably
far from unveiling the last of them. Here we report the discovery
of a potentially new class of TLR and cytokine receptor signaling
regulators: miRNAs.
We have identified by means of expression profiling several
miRNA genes, namely miR-146ab, miR-132, and miR-155, which
are induced in the human monocytic cell line THP-1 by LPS, as well
as other microbial components and proinflammatory mediators.
Through promoter studies we have determined that LPS-mediated
elevation of miR-146a expression occurs in an NF-B-dependent
manner. Finally, we have identified IRAK1 and TRAF6 as target
genes of miR-146 posttranslational repression, suggesting a novel
mechanism of negative feedback regulation of TLR and cytokine
receptor signaling.
Induction of miR-146ab by the TLR system displays a suggestive
pattern: TLRs that recognize bacterial constituents and reside on
the cell surface (1, 38) (like TLR2, TLR4, and TLR5) trigger
miR-146ab induction; those TLRs that mainly sense viral nucleic
acids and localize intracellularly (1, 38) (TLR3, TLR7, and TLR9)
have little effect on miR-146ab expression.
The dual occurrence of miR-146 found in humans is not evolu-
tionarily conserved. Search of the miRNA registry (release 7.1) (39)
reveals that the chicken and fish genomes also have two copies of
miR-146 but that rodents possess only one (Fig. 4). All miR-146
species that have been cloned differ by only 1 or 2 nt at their 3 end,
a region that is believed to play only a compensatory role in the
target recognition mechanism (33). It will be interesting to deter-
mine whether these minor variations in miR-146a and miR-146b
sequences affect their target specificity and physiological role or
whether these two genes have redundant functions and are only
differentially regulated at the transcriptional and transcript pro-
cessing levels.
The results from computational miRNA target prediction algo-
rithms included many more potential targets than we tested, but the
TRAF6 and IRAK1 genes yielded particularly high scores. Thus,
miR-146, like many mammalian miRNAs, may target a wide
spectrum of gene targets, suggesting that it could be involved in
regulation of multiple independent physiological processes. It is
noteworthy that miR-146 already has been implicated in a number
of cellular processes (14, 40, 41), and it will be important to
determine whether all of them converge on TRAF6 and IRAK1
and perhaps a few other targets.
It has been reported that miR-146a expression might be involved
in cell fate determination in mouse lymphocytes, because its level
is substantially increased in T helper 1 cells and decreased in T
helper 2 cells relative to its expression in naı¨ve T cells (14). T helper
1 differentiation and secretion of IFN by this T cell subset are
controlled primarily by the synergistic action of the IL-12 and IL-18
cytokines (42), thus suggesting a possible explanation for the
elevated levels of miR-146a in T helper 1 cells. IL-18 receptor
triggers NF-B signaling among other pathways and employs
TRAF6 and IRAK1 for its activation (43). On the other hand,
miR-146a transcription might also be regulated by the STAT family,
which mediates IL-12 effects in T cells (42).
Although the inflammatory response is valuable for dealing with
pathogens, it takes a toll on the body and, if unregulated, can lead
to serious disease. Thus, understanding the negative regulators of
the response is critically important. Most of the studied attenuating
mechanisms of inflammation involve negative transcriptional feed-
back loops, like the proteins IB and A20 (3). We can now add
miRNAs to the list of potential negative regulators of inflammation.
This is a feedback system whereby bacterial components induce
NF-B through a MyD88-dependent pathway, resulting in up-
regulation of the miR-146 genes, which, upon processing, could
down-regulate levels of IRAK1 and TRAF6 proteins, reducing the
activity of the pathway. It is noteworthy that in this scenario the
TRIF-dependent, antiviral pathway induced by TLR4 and others
will remain intact. In agreement with current knowledge on the
miRNA mode of inhibition, it seems likely that miR-146 regulatory
circuit fine-tunes TLR and cytokine signaling, rather than totally
abrogating the signal. Loss of function and overexpression studies
in cell culture as well as in animal models will help to identify the
exact role for miR-146 in immune and inflammatory responses.
Thorough analysis of the regulatory mechanisms maintaining the
balance of TLR signaling can identify key pathway molecules and
contribute to rational target selection for therapeutic intervention.
Materials and Methods
Reagents. Peptidoglycan (E. coli strain 0111:B4), CpG oligonu-
cleotide type C, synthetic bacterial lipoprotein Pam3CSK4,
ultrapure LPS (S. minnesota and E. coli strain K12), poly(I:C),
recombinant f lagellin (Salmonella typhimurium), and imi-
quimod-R837 were purchased from InvivoGen (San Diego, CA).
LPS (E. coli 055:B5) and phorbol myristyl acetate were obtained
from Sigma (St. Louis, MO), and ionomycin was from Calbio-
chem (La Jolla, CA). Recombinant human IL-1 was purchased
from Cell Sciences (Canton, MA), human CD40L was from R &
D Systems (Minneapolis, MN), and human TNF was from
Biosource International (Camarillo, CA).
miRNA Microarray Analysis. THP-1 cells were stimulated with 1
gml LPS from E. coli strain 055:B5 for 8 h, and total RNA
samples were isolated by using the mirVana RNA Isolation kit
(Ambion, Austin, TX) according to the manufacturer’s protocol.
Forty micrograms of total RNA was enriched for small RNA
species, tailed by using the mirVana miRNA Labeling kit (Am-
bion), and fluorescently labeled by using amine-reactive Cy3 and
Cy5 dyes (Amersham Pharmacia, Piscataway, NJ). The fluores-
cently labeled RNAs from control (Cy3-labeled) and LPS-treated
(Cy5-labeled) cells were mixed and hybridized for 14 h with miRNA
array slides. Microarrays were prepared by robotic spotting of DNA
oligonucleotide probes complementary to 200 miR sequences
(mirVana miRNA Probe Set, Ambion) on epoxy-coated slides
(Schott Nexterion, Louisville, KY) in quadruplicate. The microar-
rays were washed as recommended by the manufacturer and
scanned by using the GenePix 4200 fluorescent scanner.
Cell Culture, RNA Isolation, and miRNA Quantitative PCR. THP-1,
U937, HL-60, and WEHI-3 were obtained from American Type
Culture Collection (Manassas, VA). 293IL-1RMD2TLR4 cells
were a kind gift from X. Li (Cleveland Clinic Foundation, Cleve-
land, OH). BJAB cells were provided by E. Kieff (Harvard
University, Boston, MA). Mono-Mac-6 cells were obtained from
the German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). THP-1, U937, HL-60, BJAB, and
WEHI-3 cells were grown in RPMI medium 1640 supplemented
with 10% FBS, 1 nonessential amino acids, 100 unitsml peni-
cillin, 100 unitsml streptomycin, and 2 mM glutamine in a humid-
ified incubator containing 5% CO2 at 37°C. 293 IL-1RMD2
TLR4 cells were maintained in DMEM supplemented with 10%
FBS, 100 unitsml penicillin, 100 unitsml streptomycin, and 2 mM
glutamine. Twenty-four hours before stimulation, 1 106 cells were
plated in RPMI medium 1640 containing 0.5% FBS. To analyze
miRNA expression, cells were treated for 8 h with the following
stimuli: 100 ngml LPS (E. coli 055:B5), 100 ngml Pam3CSK4, 10
gml peptidoglycan, 5 M CpG oligonucleotide type C, 10 gml
ultrapure LPS (from S. minnesota and E. coli strain K12), 25 gml
poly(I:C), 100 ngml recombinant flagellin (S. typhimurium), 5
gml imiquimod-R837, 10 ngml human TNF, 10 ngml human
IL-1, 300 ngml human CD-40L, and 50 ngml phorbol myristyl
acetate in combination with 1 M ionomycin. Total RNA was
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isolated by using the mirVana miRNA Isolation kit (Ambion).
miRNA expression was measured and quantified by using the
mirVana qRT-PCR miRNA Detection Kit (Ambion) or by Taq-
Man MicroRNA Assays (Applied Biosystems, Foster City, CA)
according to the manufacturers’ protocol and normalized by 5S
rRNA levels.
Northern Blot Analysis and Cloning ofmiR-146ab Primary Transcripts.
Cells were starved for 24 h before stimulation in RPMI medium
1640 containing 0.5% FBS and then stimulated with LPS for 8 h.
Total RNA was isolated from cells by using the mirVana miRNA
Isolation kit (Ambion) or TRI-reagent (Molecular Research Cen-
ter, Cincinnati, OH). For detection of mature miRNA species, 20
g of total RNA was loaded on 12% polyacrylamide denaturing gel
along with -32P-labeled Decade Marker (Ambion) and transferred
to GeneScreenPlus membrane (PerkinElmer, Boston, MA) by
electrotransfer using semidry Transblot apparatus (Bio-Rad, Her-
cules, CA). Membranes were hybridized in ULTRAhyb-Oligo
solution (Ambion) as recommended by the manufacturer using
-32P-labeled DNA oligonucleotide probes complementary to ma-
ture forms of tested miRNAs. For pri-miR-146ab detection, 15g
of total RNA was separated on 1.2% formaldehyde-containing
agarose gel and transferred to GeneScreenPlus membrane by
capillary transfer. Hybridizations were performed in ULTRAhyb
solution (Ambion) with probes corresponding to pre-miR-146ab.
The probes were -32P-labeled with the HexaLabel DNA Labeling
Kit (Fermentas, Hanover, MD). To determine the sequence of
pri-miR-146ab, we carried out 3- and 5-RACE using the
SMART RACE cDNA amplification kit (CLONTECH, Mountain
View, CA) according to the manufacturer’s instructions.
Promoter and 3 UTR Luciferase Reporter Assays. To create cmv-
146A, cmv-146B, and cmv-21 vectors, genomic fragments (300
bp) corresponding to pre-miR-146ab isoforms and pre-miR-21
were amplified from human genomic DNA and cloned into ex-
pression vector pcDNA3 (Invitrogen, Carlsbad, CA). When trans-
fected into 293IL-1RTLR4MD2 cells, these constructs produce
mature miRNA, as assessed by Northern blot and qPCR. For
promoter luciferase reporter assays, 293IL-1RTLR4MD2 cells
were plated at 105 cells per well in 24-well dishes and transfected
24 h later by the calcium phosphate method. Each transfection
reaction contained 100 ng of miR-146a promoter fragment in
pGL3-basic vector (Promega, Madison, WI) and 200 ng of pcDNA3
as carrier. For normalization of transfection efficiency and extract
recovery, all samples included 10 ng of the pCSK-lacZ vector, which
constitutively expresses -galactosidase and is unaffected by NF-
B. Luciferase and -galactosidase activities were measured as
described elsewhere (44). To create 3 UTR luciferase reporter
constructs, fragments (500 bp) of 3 UTRs of IRAK1, TRAF6,
and COT1 genes were cloned downstream of CMV-driven firefly
luciferase cassette in pMIR-REPORT vector (Ambion). Mutated
versions of these constructs, carrying 4-bp substitutions in the
miR-146 target sites, were obtained by site-directed mutagenesis.
For miRNA target validation studies, 105 293IL-1RTLR4MD2
cells in a 24-well dish were transiently transfected with 10 ng of each
firefly luciferase reporter plasmid, 10 ng of pCSK-lacZ vector, and
300 ng of cmv-146A, cmv-146B, or cmv-21.
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